Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Research Hypothesis: Subjects in the study population who are treated with cetuximab in
combination with irinotecan will have higher response rates than subjects treated with
irinotecan alone.